Logo image of ALXN

Alexion Pharm Inc (ALXN) Stock News

NASDAQ:ALXN - Nasdaq -

182.5  +3.05 (+1.7%)

After market: 183 +0.5 (+0.27%)

ALXN Latest News, Press Relases and Analysis

News Image
a year ago - Bloomberg

Ex-Pharma Executive Avoids Prison for Tipping Pal About Merger

A former Alexion Pharmaceuticals Inc. executive avoided jail after pleading guilty to sharing information about the company’s planned purchase of another company in 2020 with a boyhood friend.

Mentions: PTLA

News Image
4 years ago - The Motley Fool

Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?

It's not likely.

Mentions: MRNA AZN

News Image
4 years ago - Zacks Investment Research

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News Image
4 years ago - Barron's

Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don't Expect More Gains.

With shares at record-high prices now, very few on Wall Street still see upside in the stock.

Mentions: MRNA SPX LB AZN

News Image
4 years ago - Zacks Investment Research

ALXN vs. TECH: Which Stock Is the Better Value Option?

ALXN vs. TECH: Which Stock Is the Better Value Option?

Mentions: TECH

News Image
4 years ago - Zacks Investment Research

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

Mentions: JNJ ABBV

News Image
4 years ago - Benzinga

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster...

Mentions: AZN

News Image
4 years ago - Zacks Investment Research

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Mentions: RGEN

News Image
4 years ago - Yahoo Finance

Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance

Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock has soared amid the pandemic after its vaccine became instrumental in the fight against coronavirus.

Mentions: VZ TSLA MRNA

News Image
4 years ago - Zacks Investment Research

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.

News Image
4 years ago - Benzinga

Moderna Options Traders Mixed On S&P 500 Inclusion

Moderna, Inc (NASDAQ: MRNA) gapped up 6.64% Friday morning after it was announced the company will join the S&P 500 beginning July 21. The pharmaceutical company,...

Mentions: SPX MRNA

News Image
4 years ago - Investor's Business Daily

Moderna Stock — Soon To Join S&P 500 — Rockets To Yet Another Record

Moderna stock rocketed to another record high Friday on news it would join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion.

Mentions: AZN MRNA AMGN PFE ...

News Image
4 years ago - InvestorPlace

MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500

Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN).

Mentions: MRNA AZN

News Image
4 years ago - Barron's

Stocks Are Higher After Retail Sales Top Expectations

Stock futures were moving higher, while Asian and European equities were mixed as Covid-19 concerns remained in focus.

Mentions: DJIA SPX COMP NIK ...

News Image
4 years ago - Barron's

Global Stocks Mixed Ahead of U.S. Retail Sales Data

Stock futures were moving higher, while Asian and European equities were mixed as Covid-19 concerns remained in focus.

Mentions: NIK 8301 UKX DJIA ...

News Image
4 years ago - Zacks Investment Research

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

Mentions: GILD ADPT GLPG

News Image
4 years ago - Zacks Investment Research

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News Image
4 years ago - Zacks Investment Research

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

News Image
4 years ago - Barron's

Vaccine Maker AstraZeneca’s Strong Drug Pipeline Could Lift the Stock Higher for Years

AstraZeneca has a Covid vaccine, but the company is also a specialist in cancer treatments, and it supplies medicine for a host of other diseases.

Mentions: AZN JNJ PFE MRK ...

News Image
4 years ago - Zacks Investment Research

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

Mentions: AZN ZTS

News Image
4 years ago - Zacks Investment Research

ALXN or GMAB: Which Is the Better Value Stock Right Now?

ALXN vs. GMAB: Which Stock Is the Better Value Option?

Mentions: GMAB

News Image
4 years ago - Investor's Business Daily

Translate Bio Stock Sees Relative Strength Rating Jump To 88

A Relative Strength Rating upgrade for Translate Bio shows improving technical performance.

Mentions: TBIO MRVI

News Image
4 years ago - Bloomberg

GlaxoSmithKline Taps Goldman and Citi for Consumer Spinoff

GlaxoSmithKline Plc has hired two banks to help advise on plans to list its consumer unit next year and defend against a potential activist campaign from Elliott Investment Management, according to people familiar with the matter.

Mentions: GS C ALKS AGN